1
|
Carrara M, Aubertin G, Khirani S, Massenavette B, Bierme P, Griffon L, Ioan I, Schweitzer C, Binoche A, Lampin ME, Mordacq C, Rubinsztajn R, Debeilleix S, Galode F, Bui S, Hullo E, Becourt A, Lubrano M, Moreau J, Renoux MC, Matecki S, Stremler N, Baravalle-Einaudi M, Mazenq J, Sigur E, Labouret G, Genevois AL, Heyman R, Pomedio M, Masson A, Hangard P, Menetrey C, Le Clainche L, Bokov P, Dudoignon B, Fleurence E, Bergounioux J, Mbieleu B, Breining A, Giovannin-Chami L, Fina A, Ollivier M, Gachelin E, Perisson C, Pervillé A, Barzic A, Cros P, Jokic M, Labbé G, Diaz V, Coutier L, Fauroux B, Taytard J. Pediatric long-term noninvasive respiratory support in children with central nervous system disorders. Pediatr Pulmonol 2024; 59:642-651. [PMID: 38088209 DOI: 10.1002/ppul.26796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 10/31/2023] [Accepted: 11/27/2023] [Indexed: 02/16/2024]
Abstract
RATIONALE The use of long-term noninvasive respiratory support is increasing in children along with an extension of indications, in particular in children with central nervous system (CNS) disorders. OBJECTIVE The aim of this study was to describe the characteristics of children with CNS disorders treated with long-term noninvasive respiratory support in France. METHODS Data were collected from 27 French pediatric university centers through an anonymous questionnaire filled for every child treated with noninvasive ventilatory support ≥3 months on 1st June 2019. MAIN RESULTS The data of 182 patients (55% boys, median age: 10.2 [5.4;14.8] years old [range: 0.3-25]) were collected: 35 (19%) patients had nontumoral spinal cord injury, 22 (12%) CNS tumors, 63 (35%) multiple disabilities, 26 (14%) central alveolar hypoventilation and 36 (20%) other CNS disorders. Seventy five percent of the patients were treated with noninvasive ventilation (NIV) and 25% with continuous positive airway pressure (CPAP). The main investigations performed before CPAP/NIV initiation were nocturnal gas exchange recordings, alone or coupled with poly(somno)graphy (in 29% and 34% of the patients, respectively). CPAP/NIV was started in an acute setting in 10% of the patients. Median adherence was 8 [6;10] hours/night, with 12% of patients using treatment <4 h/day. Nasal mask was the most common interface (70%). Airway clearance techniques were used by 31% of patients. CONCLUSION CPAP/NIV may be a therapeutic option in children with CNS disorders. Future studies should assess treatment efficacy and patient reported outcome measures.
Collapse
Affiliation(s)
- Marion Carrara
- Department of Pediatric Pulmonology, AP-HP, Hôpital Armand Trousseau, Paris, France
| | - Guillaume Aubertin
- Department of Pediatric Pulmonology, AP-HP, Hôpital Armand Trousseau, Paris, France
- Sorbonne Université, INSERM UMR-S 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
- Centre de pneumologie de l'enfant, Ramsay Générale de Santé, Paris, France
| | - Sonia Khirani
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker-Enfants malades, Paris, France
- Université Paris Cité, VIFASOM, Paris, France
- ASV Santé, Gennevilliers, France
| | - Bruno Massenavette
- Pediatric Intensive Care Unit, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Bron, France
| | - Priscille Bierme
- Pediatric Pulmonology and Allergology Unit, Hospices Civils de Lyon, Bron, France
| | - Lucie Griffon
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker-Enfants malades, Paris, France
- Université Paris Cité, VIFASOM, Paris, France
| | - Iulia Ioan
- Department of Pediatric, University Children's Hospital, CHRU Nancy; Université de Lorraine, DevAH, Nancy, France
| | - Cyril Schweitzer
- Department of Pediatric, University Children's Hospital, CHRU Nancy; Université de Lorraine, DevAH, Nancy, France
| | - Alexandra Binoche
- Pediatric Intensive Care Unit, Hôpital Jeanne de Flandre, CHU Lille, Lille, France
| | - Marie-Emilie Lampin
- Pediatric Intensive Care Unit, Hôpital Jeanne de Flandre, CHU Lille, Lille, France
| | - Clémence Mordacq
- Pediatic Pulmonology and Allergology Unit, Hôpital Jeanne de Flandre, CHU Lille, Lille, France
| | - Robert Rubinsztajn
- Department of Pediatric orthopedic surgery, Hôpital Necker-Enfants malades, Paris, France
| | | | - François Galode
- Pediatric Pulmonology Unit, Hôpital Pellegrin-Enfants, Bordeaux, France
| | - Stéphanie Bui
- Pediatric Pulmonology Unit, Hôpital Pellegrin-Enfants, Bordeaux, France
| | - Eglantine Hullo
- Pediatric Pulmonology Unit, Hôpital Couple-Enfant, CHU Grenoble, Grenoble, France
| | - Arnaud Becourt
- Pediatric Pulmonology Department, CHU Amiens Picardie, Amiens, France
| | - Marc Lubrano
- Respiratory Diseases, Allergy and CF Unit, Department of Pediatric, University Hospital Charles Nicolle, Rouen, France
| | - Johan Moreau
- Department of Pediatric Cardiology and Pulmonology, Montpellier University Hospital, Montpellier, France
- Physiology and Experimental Biology of Heart and Muscles Laboratory-PHYMEDEXP, UMR CNRS 9214, INSERM U1046, University of Montpellier, Montpellier, France
| | - Marie-Catherine Renoux
- Department of Pediatric Cardiology and Pulmonology, Montpellier University Hospital, Montpellier, France
| | - Stefan Matecki
- Department of Pediatric Cardiology and Pulmonology, Montpellier University Hospital, Montpellier, France
- Functional Exploration Laboratory, University Hospital, Montpellier, France
| | - Nathalie Stremler
- Pediatric Ventilation Unit, Department of Pediatric, AP-HM, Hôpital La Timone, Marseille, France
| | | | - Julie Mazenq
- Pediatric Ventilation Unit, Department of Pediatric, AP-HM, Hôpital La Timone, Marseille, France
| | - Elodie Sigur
- Pediatric Pulmonology and Allergology Unit, Hôpital des Enfants, Toulouse, France
| | - Géraldine Labouret
- Pediatric Pulmonology and Allergology Unit, Hôpital des Enfants, Toulouse, France
| | - Anne-Laure Genevois
- Pediatric Pulmonology and Allergology Unit, Hôpital des Enfants, Toulouse, France
| | - Rachel Heyman
- Pediatric Unit, Department of Physical Medicine and Rehabilitation, Hôpital Pontchaillou, Rennes, France
| | - Michael Pomedio
- Pediatric Intensive Care Unit, American Memorial Hospital, CHU Reims, Reims, France
| | - Alexandra Masson
- Pediatric Unit, Hôpital de la Mère et de l'Enfant, Limoges, France
| | - Pauline Hangard
- Pediatric Unit, Hôpital de la Mère et de l'Enfant, Limoges, France
| | - Céline Menetrey
- Pediatric Unit, Hôpital de la Mère et de l'Enfant, Limoges, France
| | - Laurence Le Clainche
- Pediatric Noninvasive Ventilation Unit, AP-HP, Hôpital Robert Debré, Paris, France
| | - Plamen Bokov
- Pediatric Noninvasive Ventilation Unit, AP-HP, Hôpital Robert Debré, Paris, France
- Université Paris Cité, INSERM NeuroDiderot, Paris, France
| | - Benjamin Dudoignon
- Pediatric Noninvasive Ventilation Unit, AP-HP, Hôpital Robert Debré, Paris, France
| | | | - Jean Bergounioux
- Pediatric Intensive Care Unit, AP-HP, Hôpital Raymond Poincaré, Garches, France
| | - Blaise Mbieleu
- Pediatric Intensive Care Unit, AP-HP, Hôpital Raymond Poincaré, Garches, France
| | | | - Lisa Giovannin-Chami
- Department of Pediatric Pulmonology and Allergology, Hôpitaux pédiatriques de Nice CHU-Lenval, Nice, France
| | - Agnes Fina
- Department of Pediatric Pulmonology and Allergology, Hôpitaux pédiatriques de Nice CHU-Lenval, Nice, France
| | | | - Elsa Gachelin
- Department of Pediatric, CHU Félix Guyon, Saint Denis, La Réunion, France
| | - Caroline Perisson
- Department of Pediatric, CHU Sud Réunion, Saint Pierre, La Réunion, France
| | - Anne Pervillé
- Department of Pédiatrics, Hôpital d'Enfants-ASFA, Saint Denis, La Réunion, France
| | | | | | - Mickaël Jokic
- Pediatric Intensive Care Unit, CHU de Caen Normandie, Caen, France
| | - Guillaume Labbé
- Pediatric Pulmonology and Allergology Unit, CHU d'Estaing, Clermont-Ferrand, France
| | - Véronique Diaz
- Department of Respiratory Physiology, CHU Poitiers, Poitiers, France
| | - Laurianne Coutier
- Pediatric Pulmonology and Allergology Unit, Hospices Civils de Lyon, Bron, France
| | - Brigitte Fauroux
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker-Enfants malades, Paris, France
- Université Paris Cité, VIFASOM, Paris, France
| | - Jessica Taytard
- Department of Pediatric Pulmonology, AP-HP, Hôpital Armand Trousseau, Paris, France
- INSERM UMR-S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", Sorbonne Université, Paris, France, Paris, France
| |
Collapse
|
2
|
Dervaux M, Thumerelle C, Fabre C, Abou-Taam R, Bihouee T, Brouard J, Clement A, Delacourt C, Delestrain C, Epaud R, Ghdifan S, Hadchouel A, Houdouin V, Labouret G, Perisson C, Reix P, Renoux MC, Troussier F, Weiss L, Mazenq J, Nathan N, Dubus JC. Long-term evolution of neuroendocrine cell hyperplasia of infancy: the FRENCHI findings. Eur J Pediatr 2023; 182:949-956. [PMID: 36449078 DOI: 10.1007/s00431-022-04734-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 11/21/2022] [Accepted: 11/23/2022] [Indexed: 12/05/2022]
Abstract
Only few studies report long-term evolution of patients with neuroendocrine cell hyperplasia of infancy (NEHI). We report data from a 54-patient cohort followed up in the French network for rare respiratory diseases (RespiRare). Demographic characteristics and respiratory and nutritional evolution were collected at the time of the patient's last scheduled visit. The mean duration of follow-up was 68 months (5 months to 18 years). Fifteen patients (27.8%) were considered clinically cured. During follow-up, hospitalizations for wheezy exacerbations were reported in 35 patients (55%), and asthma diagnosed in 20 (37%). Chest CT scan improvement was noted in 25/44 (56.8%). Spirometry showed a persistent obstructive syndrome in 8/27 (29.6%). A sleep disorder was rare (2/36, 5.5%). Oxygen weaning occurred in 28 of the 45 patients initially treated (62.2%) and was age-dependent (35.7% under 2 years, 70.5% between 2 and 6 years, and 100% after 7 years). Oxygen duration was linked to a biopsy-proven diagnosis (p = 0.02) and to the use of a nutritional support (p = 0.003). Corticosteroids were largely prescribed at diagnosis, with no evident respiratory or nutritional effect during follow-up. Among 23 patients with an initial failure to thrive, 12 (52.2%) had no weight recovery. Initial enteral feeding (17/54, 31.5%) was stopped at a mean age of 43 months (3 to 120), with no effect on cure and oxygen liberation at the last visit. Conclusion: Our results show that NEHI has a globally positive, but unequal, improvement over time. Further prospective studies are needed to better clarify the different trajectories of patients with NEHI. What is Known: • Neuroendocrine cell hyperplasia of infancy (NEHI) is an interstitial lung disease whose long-term outcome is considered positive from very few studies including heterogeneous populations. What is New: • The 68-month follow-up of our 54-patient cohort showed respiratory/nutritional symptom persistence in 72.2%, oxygen requiring in 34%, and asthma in 37%. When controlled, radiological or functional improvement was noted in 56.8 and 40.7%. Further prospective studies are needed to better clarify the different trajectories of patients with NEHI.
Collapse
Affiliation(s)
- Morgane Dervaux
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France
| | - Caroline Thumerelle
- Pediatric Pulmonology and Allergy Department, Jeanne de Flandre Hospital, CHU Lille, Univ. Lille, Pole Enfant, Lille, France
| | - Candice Fabre
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France
| | - Rola Abou-Taam
- Reference Center for Rare Lung Diseases, Pediatric Pulmonology Department, University Hospital of Necker-Enfants Malades, AP-HP, Paris, France
| | - Tiphaine Bihouee
- Chronic Childhood Diseases Unit, Pediatric Department, Nantes University Hospital, Nantes, France
| | - Jacques Brouard
- Service de Pédiatrie Médicale, CHU Caen, Caen, et UMR1311 DYNAMICURE, Normandie Université, UNICAEN, UNIROUEN, Rouen, France
| | - Annick Clement
- Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), AP‑HP, Sorbonne University, Inserm UMR S-933 Childhood Genetic Disorders, Armand Trousseau Hospital, Paris, France
| | - Christophe Delacourt
- Reference Center for Rare Lung Diseases, Pediatric Pulmonology Department, University Hospital of Necker-Enfants Malades, AP-HP, Paris, France
| | - Céline Delestrain
- Center for Rare Lung Diseases (RespiRare), Centre Hospitalier Intercommunal of Créteil, University Paris Est Créteil, INSERM, IMRB, Créteil, France
| | - Ralph Epaud
- Center for Rare Lung Diseases (RespiRare), Centre Hospitalier Intercommunal of Créteil, University Paris Est Créteil, INSERM, IMRB, Créteil, France
| | - Sofiane Ghdifan
- Pediatric Unit, Grenoble-Alpes University Hospital, Grenoble, France
| | - Alice Hadchouel
- Reference Center for Rare Lung Diseases, Pediatric Pulmonology Department, University Hospital of Necker-Enfants Malades, AP-HP, Paris, France
| | - Véronique Houdouin
- Pediatric Pulmonology Department, INSERM UMR S 976 Human Immunology, AP-HP, Paris University Robert Debre Hospital, Paris, France
| | - Géraldine Labouret
- Pediatric Pulmonology Department, University Hospital for Children, Toulouse, France
| | - Caroline Perisson
- Pediatric Unit, University Hospital Sud Reunion, Saint-Pierre, France
| | - Philippe Reix
- Pediatric Pulmonology, Allergology Cystic Fibrosis Department, Hospices Civils of Lyon, Hôpital Femme Mère Enfant, Bron, France.,UMR 5558, CNRS Equipe, EMET University, Claude Bernard Lyon 1, Lyon, France
| | - Marie-Catherine Renoux
- Paediatric Cardiology and Pulmonology Department, Montpellier University Hospital, Montpellier, France
| | | | - Laurence Weiss
- Specialized Pediatric Department, University Hospital of Strasbourg, Strasbourg, France
| | - Julie Mazenq
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France
| | - Nadia Nathan
- Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), AP‑HP, Sorbonne University, Inserm UMR S-933 Childhood Genetic Disorders, Armand Trousseau Hospital, Paris, France
| | - Jean-Christophe Dubus
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France. .,Aix Marseille University, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France. .,Unité de Pneumopédiatrie, CHU Timone-Enfants, 13385 Cedex 5, Marseille, France.
| |
Collapse
|
3
|
Fabre C, Thumerelle C, Dervaux M, Abou-Taam R, Bihouee T, Brouard J, Clement A, Delacourt C, Delestrain C, Epaud R, Ghdifan S, Hadchouel A, Houdouin V, Labouret G, Perisson C, Reix P, Renoux MC, Troussier F, Weiss L, Mazenq J, Nathan N, Dubus JC. French national cohort of neuroendocrine cell hyperplasia of infancy (FRENCHI) study: diagnosis and initial management. Eur J Pediatr 2022; 181:3067-3073. [PMID: 35678871 DOI: 10.1007/s00431-022-04510-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 05/11/2022] [Accepted: 05/14/2022] [Indexed: 11/03/2022]
Abstract
UNLABELLED Early diagnosis of neuroendocrine cell hyperplasia of infancy (NEHI) is crucial as, conversely to the other causes of intersititial lung disease, corticosteroids are not recommended. Diagnosis is historically based on lung biopsy (NEHI), but in current practice, a clinical and radiological approach is more and more preferred (NEHI syndrome). This national study aimed to address diagnosis and initial management of patients followed up for a NEHI pattern in pediatric centers for rare lung diseases (RespiRare, France). Data on neonatal and familial events, symptoms at diagnosis, explorations performed and results, and therapeutic management were collected by questionnaire. Fifty-four children were included (boys 63%). The mean onset of symptoms was 3.8 ± 2.6 months. The most frequent symptoms at diagnosis were tachypnea (100%), retraction (79.6%), crackles (66.7%), and hypoxemia (59.3%). The mean NEHI clinical score, evocative when ≥ 7/10, was 7.9 ± 1.4 (76% with a score ≥ 7). All chest CT-scans showed ground glass opacities evolving at least the middle lobe and the lingula. Lung biopsy was performed in 38.9% of the cases and was typical of NEHI in only 52.4%, even when the clinical presentation was typical. Initial treatments were oxygen (83.6%) and more curiously intravenous pulses of steroids (83.3%) and azithromycin (70.2%). CONCLUSION This national cohort of patients underlines diagnosis difficulties of NEHI. A composite clinical and radiological score should help clinicians for limiting the use of anti-inflammatory drugs. WHAT IS KNOWN •Neuroendocrine cell hyperplasia of infancy (NEHI) is an interstitial lung disease whose diagnosis is essential to limit corticosteroids therapy. WHAT IS NEW •In this national cohort of 54 patients with a NEHI pattern, diagnosis is mainly based on clinical symptoms and chest CT-scan results. The newly proposed clinical score and, when performed, the lung biopsies are faulted in 25 and 50% of the cases, respectively. •Corticosteroids are widely used. Such results plead for a new composite score to formally diagnose NEHI.
Collapse
Affiliation(s)
- Candice Fabre
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France
| | - Caroline Thumerelle
- Pediatric Pulmonology and Allergy Department, Jeanne de Flandre Hospital, CHU Lille, Univ. Lille, Pole Enfant, Lille, France
| | - Morgane Dervaux
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France
| | - Rola Abou-Taam
- AP-HP, Pediatric Pulmonology Department, Reference Center for Rare Lung Diseases, University Hospital of Necker-Enfants Malades, Paris, France
| | - Tiphaine Bihouee
- Chronic Childhood Diseases Unit, Pediatric Department, Nantes University Hospital, Nantes, France
| | - Jacques Brouard
- Service de Pédiatrie Médicale, CHU Caen, Caen, et UMR1311 DYNAMICURE, Normandie Université, UNICAEN, UNIROUEN, Rouen, France
| | - Annick Clement
- AP-HP, Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Sorbonne University, Inserm UMR S-933 Childhood Genetic Disorders, Armand Trousseau Hospital, Paris, France
| | - Christophe Delacourt
- AP-HP, Pediatric Pulmonology Department, Reference Center for Rare Lung Diseases, University Hospital of Necker-Enfants Malades, Paris, France
| | - Céline Delestrain
- Center for Rare Lung Diseases (RespiRare), Centre Hospitalier Intercommunal of Créteil, University Paris Est Créteil, INSERM, IMRB, Créteil, France
| | - Ralph Epaud
- Center for Rare Lung Diseases (RespiRare), Centre Hospitalier Intercommunal of Créteil, University Paris Est Créteil, INSERM, IMRB, Créteil, France
| | - Sofiane Ghdifan
- Pediatric Unit, Grenoble-Alpes University Hospital, Grenoble, France
| | - Alice Hadchouel
- AP-HP, Pediatric Pulmonology Department, Reference Center for Rare Lung Diseases, University Hospital of Necker-Enfants Malades, Paris, France
| | - Véronique Houdouin
- AP-HP, Pediatric Pulmonology Department, UMR S 976 INSERM Human Immunology, Paris University, Robert Debre Hospital, Paris, France
| | - Géraldine Labouret
- Pediatric Pulmonology Department, University Hospital for Children, Toulouse, France
| | - Caroline Perisson
- Pediatric Unit, University Hospital Sud Reunion, Saint-Pierre, France
| | - Philippe Reix
- Pediatric Pulmonology, Allergology, Cystic Fibrosis Department, Hospices Civils of Lyon, Hôpital Femme Mère Enfant, Bron, France.,UMR 5558, Equipe EMET, CNRS, University Claude Bernard Lyon 1, Lyon, France
| | - Marie-Catherine Renoux
- Paediatric Cardiology and Pulmonology Department, Montpellier University Hospital, Montpellier, France
| | | | - Laurence Weiss
- Specialized Pediatric Department, University Hospital of Strasbourg, Strasbourg, France
| | - Julie Mazenq
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France
| | - Nadia Nathan
- AP-HP, Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases (RespiRare), Sorbonne University, Inserm UMR S-933 Childhood Genetic Disorders, Armand Trousseau Hospital, Paris, France
| | - Jean-Christophe Dubus
- Pediatric Pulmonology Department, University Timone Hospital for Children, AP-HM, Marseille, France. .,IRD, Aix Marseille University, MEPHI, IHU Méditerranée Infection, Marseille, France. .,Unité de Pneumopédiatrie, CHU Timone-Enfants, 13385, Cedex 5/0491386816, Marseille, France.
| |
Collapse
|
4
|
Lauby C, Boelle PY, Abou Taam R, Bessaci K, Brouard J, Dalphin ML, Delacourt C, Delestrain C, Deschildre A, Dubus JC, Fayon M, Giovannini-Chami L, Houdouin V, Houzel A, Marguet C, Pin I, Reix P, Renoux MC, Schweitzer C, Tatopoulos A, Thumerelle C, Troussier F, Wanin S, Weiss L, Clement A, Epaud R, Nathan N. Health-related quality of life in infants and children with interstitial lung disease. Pediatr Pulmonol 2019; 54:828-836. [PMID: 30868755 DOI: 10.1002/ppul.24308] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Revised: 01/27/2019] [Accepted: 02/17/2019] [Indexed: 11/06/2022]
Abstract
INTRODUCTION Interstitial lung disease in children (chILD) is a highly heterogeneous group of rare and severe respiratory disorders. The disease by itself, the burden of the treatments (oxygen therapy, corticosteroid pulses, nutritional support) and recurrent hospitalizations may impair the quality of life (QoL) of these children. The aim of the study was to compare the health-related QoL (HR-QoL) in chILD compared to a healthy population and to find out the predictive factors of an altered QoL. METHODS Patients aged 1 month to 18 years with ILD of known or unknown etiology were prospectively included. Parents and children over 8 years old were asked to fill the PedsQL 4.0 Generic Core Scale ranging from 0 to 100 points. RESULTS A total of 78 children were recruited in 13 French pediatric centers. Total scores were 11.94 points (P = 0.0003) less for child self-report and 14.08 points ( P < 0.0001) less for parent proxy-report with respect to the healthy population. The clinical factors associated with a lower total score were: extrapulmonary expression of the disease, higher Fan severity score, long-term oxygen therapy, nutritional support, and a number of oral treatments. CONCLUSION Using a validated quality of life (QoL) scale, we showed that health-related-QoL is significantly impaired in chILD compared with a healthy population. Factors altering QoL score are easy to recognize and could help identify children at a heightened risk of low QoL.
Collapse
Affiliation(s)
- Clara Lauby
- Reference Centre for Rare Lung Diseases, RespiRare, France
| | - Pierre-Yves Boelle
- Inserm UMR S 1136, Pierre Louis Institute of Epidemiology and Public Health, Paris, France
| | - Rola Abou Taam
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, APHP, Necker Enfants Malades Hospital, Paris, France
| | - Katia Bessaci
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Reims, France
| | - Jacques Brouard
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Caen, France
| | - Marie-Laure Dalphin
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Besançon, France
| | - Christophe Delacourt
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, APHP, Necker Enfants Malades Hospital, Paris, France
| | - Céline Delestrain
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France
| | - Antoine Deschildre
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Lille, France
| | - Jean-Christophe Dubus
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, La Timone University Hospital, Marseille, France
| | - Michaël Fayon
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, Pellegrin University Hospital, Bordeaux, France
| | - Lisa Giovannini-Chami
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, Lenval University Hospital, Nice, France
| | - Véronique Houdouin
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, APHP, Robert Debré Hospital, Paris, France
| | - Anne Houzel
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Dijon, France
| | - Christophe Marguet
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Rouen, France
| | - Isabelle Pin
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Grenoble, France
| | - Philippe Reix
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, Femme Mere Enfants University Hospital, Hospices Civils de Lyon, Lyon, France
| | - Marie-Catherine Renoux
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Montpellier, France
| | - Cyril Schweitzer
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Nancy, France
| | - Aurélie Tatopoulos
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Nancy, France
| | - Caroline Thumerelle
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Lille, France
| | - Françoise Troussier
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Angers, France
| | - Stéphanie Wanin
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, APHP, Robert Debré Hospital, Paris, France
| | - Laurence Weiss
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, University Hospital, Strasbourg, France
| | - Annick Clement
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department and Inserm UMR S933, APHP and Sorbonne Université, Armand Trousseau Hospital, Paris, France
| | - Ralph Epaud
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France
| | - Nadia Nathan
- Reference Centre for Rare Lung Diseases, RespiRare, France.,Pediatric Pulmonology Department and Inserm UMR S933, APHP and Sorbonne Université, Armand Trousseau Hospital, Paris, France
| |
Collapse
|
5
|
Romieu H, Charbonnier F, Janka D, Douillard A, Macioce V, Lavastre K, Abassi H, Renoux MC, Mura T, Amedro P. Efficiency of physiotherapy with Caycedian Sophrology on children with asthma: A randomized controlled trial. Pediatr Pulmonol 2018; 53:559-566. [PMID: 29493875 DOI: 10.1002/ppul.23982] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 01/25/2018] [Indexed: 11/08/2022]
Abstract
BACKGROUND Asthma is the most common chronic disease in pediatrics. Along with the usual drug therapy using corticosteroids and bronchodilators, some interest has been shown for adjuvant therapies, such as sophrology. However, the level of evidence for non-pharmaceutical therapies in asthma remains low, especially in children. This study aimed to assess whether in children with asthma, peak expiratory flow (PEF) improved more after a sophrology session alongside standard treatment than after standard treatment alone. METHODS We carried out a prospective randomized controlled clinical trial among 74 children aged 6-17 years old, hospitalized for an asthma attack. Group 1: conventional treatment (oxygen, corticosteroids, bronchodilators, physiotherapy) added to one session of sophrology. Group 2: conventional treatment alone. The primary outcome was the PEF variation between the initial and final evaluations (PEF2 -PEF1 ). RESULTS Demographic and clinical characteristics were similar in both groups at baseline. Measures before and after the sophrology session showed that the PEF increased by mean 30 L/min in the sophrology group versus 20 L/min in the control group (P = 0.02). Oxygen saturation increased by 1% versus 0% (P = 0.02) and the dyspnea score with visual analogue scale improved by two points point (P = 0.01). No differences were observed between the two groups in terms of duration of hospitalization, use and doses of conventional medical treatment (oxygen, corticosteroids, and bronchodilators), and quality of life scores. CONCLUSIONS Sophrology appears as a promising adjuvant therapy to current guideline-based treatment for asthma in children.
Collapse
Affiliation(s)
- Huguette Romieu
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France
| | - Françoise Charbonnier
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France
| | - Dora Janka
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France
| | - Aymeric Douillard
- Department of Epidemiology and Clinical Research, University Hospital, Montpellier, France
| | - Valérie Macioce
- Department of Epidemiology and Clinical Research, University Hospital, Montpellier, France
| | - Kathleen Lavastre
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France
| | - Hamouda Abassi
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France.,Self-Perceived Health Assessment Research Unit, EA3279, Department of Public Health, Mediterranean Medical School, Marseille, France
| | - Marie-Catherine Renoux
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France
| | - Thibault Mura
- Department of Epidemiology and Clinical Research, University Hospital, Montpellier, France.,INSERM U1061, University of Montpellier, Montpellier, France
| | - Pascal Amedro
- Department of Pediatric Cardiology and Pulmonology, University Hospital, Montpellier, France.,Physiology and Experimental Biology of Heart and Muscles Laboratory-PHYMEDEXP, UMR CNRS 9214-INSERM U1046, University of Montpellier, Montpellier, France.,Self-Perceived Health Assessment Research Unit, EA3279, Department of Public Health, Mediterranean Medical School, Marseille, France
| |
Collapse
|
6
|
Alimi A, Taytard J, Abou Taam R, Houdouin V, Forgeron A, Lubrano Lavadera M, Cros P, Gibertini I, Derelle J, Deschildre A, Thumerelle C, Epaud R, Reix P, Fayon M, Roullaud S, Troussier F, Renoux MC, de Blic J, Leyronnas S, Thouvenin G, Perisson C, Ravel A, Clement A, Corvol H, Nathan N. Pulmonary hemosiderosis in children with Down syndrome: a national experience. Orphanet J Rare Dis 2018; 13:60. [PMID: 29678139 PMCID: PMC5910623 DOI: 10.1186/s13023-018-0806-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 04/12/2018] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Pulmonary hemosiderosis is a rare and complex disease in children. A previous study from the French RespiRare® network led to two important findings: 20% of the children presented with both pulmonary hemosiderosis and Down syndrome (DS), and at least one tested autoantibody was found positive in 50%. This study investigates the relationships between pulmonary hemosiderosis and DS. METHODS Patients younger than 20 years old and followed for pulmonary hemosiderosis were retrieved from the RespiRare® database. Clinical, biological, functional, and radiological findings were collected, and DS and non-DS patients' data were compared. RESULTS A total of 34 patients (22 girls and 12 boys) were included, among whom nine (26%) presented with DS. The mean age at diagnosis was 4.1 ± 3.27 years old for non-DS and 2.9 ± 3.45 years old for DS patients. DS patients tended to present a more severe form of the disease with an earlier onset, more dyspnoea at diagnosis, more frequent secondary pulmonary hypertension, and an increased risk of fatal evolution. CONCLUSIONS DS patients have a higher risk of developing pulmonary hemosiderosis, and the disease seems to be more severe in this population. This could be due to the combination of an abnormal lung capillary bed with fragile vessels, a higher susceptibility to autoimmune lesions, and a higher risk of evolution toward pulmonary hypertension. A better screening for pulmonary hemosiderosis and a better prevention of hypoxia in DS paediatric patients may prevent a severe evolution of the disease.
Collapse
Affiliation(s)
- Aurelia Alimi
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
| | - Jessica Taytard
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
| | - Rola Abou Taam
- APHP, Pediatric Pulmonology department, RespiRare, Necker Enfants Malades Hospital , 75015 Paris, France
| | - Véronique Houdouin
- APHP, Pediatric Pulmonology department, RespiRare, Faculty Paris Diderot VII, Inserm U1149, Robert Debré Hospital, Paris, France
| | - Aude Forgeron
- Pediatric department, Hospital Center, Inserm U646, 72037 Le Mans, France
| | | | - Pierrick Cros
- Pediatric Pulmonology department, University Hospital, Inserm 1078, Brest, France
| | | | | | - Antoine Deschildre
- Pediatric Pulmonology department, University Hospital, UMR CNRS 8204 - Inserm U1019, Lille, France
| | - Caroline Thumerelle
- Pediatric Pulmonology department, University Hospital, UMR CNRS 8204 - Inserm U1019, Lille, France
| | - Ralph Epaud
- Pediatric Pulmonology department, RespiRare, Créteil University Hospital, Inserm U955, Créteil, France
| | - Philippe Reix
- Pediatric Pulmonology department, University Hospital, UMR CNRS 5558, Lyon, France
| | - Michael Fayon
- Pediatric Pulmonology department, University Hospital, U1219, Bordeaux, France
| | | | - Françoise Troussier
- Pediatric Pulmonology department, University Hospital, Inserm U892, Angers, France
| | - Marie-Catherine Renoux
- Pediatric Pulmonology department, University Hospital, Inserm U1046, Montpellier, France
| | - Jacques de Blic
- APHP, Pediatric Pulmonology department, RespiRare, Necker Enfants Malades Hospital , 75015 Paris, France
| | - Sophie Leyronnas
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
| | - Guillaume Thouvenin
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
- Sorbonne Université, Inserm UMR-S938, Paris, France
| | - Caroline Perisson
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
| | | | - Annick Clement
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
- Sorbonne Université, Inserm UMR-S933, Paris, France
| | - Harriet Corvol
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
- Sorbonne Université, Inserm UMR-S938, Paris, France
| | - Nadia Nathan
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
- Sorbonne Université, Inserm UMR-S933, Paris, France
| | - for the French RespiRare® group
- Assistance Publique Hôpitaux de Paris (APHP), Pediatric Pulmonology department and Reference centre for rare lung diseases, RespiRare, Trousseau Hospital, 75012 Paris, France
- APHP, Pediatric Pulmonology department, RespiRare, Necker Enfants Malades Hospital , 75015 Paris, France
- APHP, Pediatric Pulmonology department, RespiRare, Faculty Paris Diderot VII, Inserm U1149, Robert Debré Hospital, Paris, France
- Pediatric department, Hospital Center, Inserm U646, 72037 Le Mans, France
- Pediatric Pulmonology department, University Hospital, Rouen, France
- Pediatric Pulmonology department, University Hospital, Inserm 1078, Brest, France
- Pediatric department, University Hospital, Tours, France
- Pediatric department, University Hospital, Nancy, France
- Pediatric Pulmonology department, University Hospital, UMR CNRS 8204 - Inserm U1019, Lille, France
- Pediatric Pulmonology department, RespiRare, Créteil University Hospital, Inserm U955, Créteil, France
- Pediatric Pulmonology department, University Hospital, UMR CNRS 5558, Lyon, France
- Pediatric Pulmonology department, University Hospital, U1219, Bordeaux, France
- Pediatric department, Hospital Centre, Angouleme, France
- Pediatric Pulmonology department, University Hospital, Inserm U892, Angers, France
- Pediatric Pulmonology department, University Hospital, Inserm U1046, Montpellier, France
- Sorbonne Université, Inserm UMR-S938, Paris, France
- Institut Jérôme Lejeune, Paris, France
- Sorbonne Université, Inserm UMR-S933, Paris, France
| |
Collapse
|
7
|
Tochon M, Bosdure E, Salles M, Beloncle C, Chadelat K, Dagorne M, Gaudelus J, Losi S, Renoux MC, Veziris N, Dubus JC. Management of young children in contact with an adult with drug-resistant tuberculosis, France, 2004-2008. Int J Tuberc Lung Dis 2011; 15:326-330. [PMID: 21333098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Abstract
SETTING Drug-resistant tuberculosis (DR-TB) is increasing worldwide and may be a source of diagnostic and therapeutic problems in young exposed children. In France exposed children are systematically treated with 3-month isoniazid-rifampicin prophylaxis. OBJECTIVE To describe the characteristics and management of children aged <2 years in contact with an adult case of DR-TB in France over a 5-year period (2004-2008). METHODS Children were retrospectively identified by sending questionnaires to all the members of the Paediatric Infectious Diseases Group and the Paediatric Pulmonology Group of the French Paediatric Society. RESULTS Ten children, all infants, in contact with an adult case of DR-TB were identified: six cases of DR-TB (mean age 4.6 months), one case of TB infection and three cases of exposure (mean age 3.1 months). The children were mainly in contact with poly- or multidrug-resistant TB. Time to initiation of appropriate treatment was 39 days for TB disease and 58 days for TB infection or exposure. One child with TB infection developed TB disease due to failure to adapt prophylaxis. Treatment was variable and centre-dependent. Short-term follow-up showed complete recovery of all children. CONCLUSION Management of young children in contact with adult DR-TB requires rapid identification of the drug resistance profile. Molecular techniques should be used to reduce delays in initiating appropriate treatment.
Collapse
Affiliation(s)
- M Tochon
- Paediatric Unit, Centre Hospitalièr Universitaire Timone-Enfants, Marseille, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
We report the case of a 5-year-old child with dyskeratosis congenita who presented cyanosis and dyspnea at exertion. He had severe hypoxemia with elevated alveolar-arterial oxygen gradient in the setting of liver disease. Technetium-99m-labeled macroaggregated albumin scan showed abnormally high uptake in the brain, confirming hepatopulmonary syndrome.
Collapse
Affiliation(s)
- M C Renoux
- Pediatric Cardiology and Pulmonology Unit, Hospital Arnaud de Villeneuve, Montpellier, France.
| | | | | | | |
Collapse
|
9
|
Renoux MC, Guyon G, Rodière M. Myosite paravertébrale à Streptococcus pyogenes A β hémolytique compliquée d'un abcès épidural chez une enfant. Arch Pediatr 2006; 13:273-5. [PMID: 16442788 DOI: 10.1016/j.arcped.2005.11.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2004] [Accepted: 11/22/2005] [Indexed: 10/25/2022]
Abstract
CASE REPORT A 5-year-old girl was hospitalised for fever, abdominal and lumbar pain, associated with general impairment state and a whitlow. One of the blood cultures and CSF grew A beta haemolytic Streptococcus, muscular echography and MRI showed paravertebral myositis, which was complicated by an epidural abscess. The outcome was good with medical treatment alone. DISCUSSION Streptococcal myositis is a rare and severe skeletal muscle infection caused by A beta haemolytic Streptococcus. It is characterized by a muscle necrosis, without abscess formation. It has to be distinguished from pyomyositis, usually caused by Staphylococcus aureus, where a muscle abscess occurs, which must be treated by surgical drainage and antibiotics. Prognosis of this infection is poorer than other muscle infections such as pyomyositis, with a high mortality rate. The diagnosis is difficult and often delayed. Practitioners should keep in mind this diagnosis, even if symptoms are non specific, in front of an undetermined infectious syndrome associated with pain, and make an echography or nuclear magnetic resonance imaging to confirm the diagnosis.
Collapse
Affiliation(s)
- M C Renoux
- Service de Maladies Infectieuses Pédiatriques, CHU Arnaud-de-Villeneuve, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 05, France
| | | | | |
Collapse
|